Progyny 3rd Quarter 2026 Earnings Conference Call - PROGYNY INC

Financial Performance:

• Q3 revenue grew nearly 9% year-over-year, exceeding guidance midpoints; first nine months saw 11% revenue growth (10.1–11.7% when excluding one transition-of-care client).
• Gross margin expanded by 130 basis points YoY, driven by lower stock compensation expense and operational efficiencies in care management.
• Adjusted EBITDA margin was modestly lower YoY on a quarterly basis but remains consistent at 17.1% on a trailing 12-month basis.
• Operating cash flow exceeded $56 million in Q3, with $207 million over the trailing 12 months, maintaining a >75% EBITDA-to-cash conversion rate for seven consecutive quarters.
• Net cash position stands at $196 million (as of Sept 30) with no outstanding debt; $200 million revolving credit facility remains undrawn.
• Share repurchases totaled nearly $83 million for ~3 million shares in Q3, reducing total shares outstanding by nearly 15% over the past year.
• DSO improved to ~66 days, down nearly seven days YoY.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $1.365–$1.385 billion (5.9–7.5% growth); excluding the transition client, growth is 10.1–11.7%.
• 2026 Adjusted EBITDA guidance raised to $235–$240 million; Net income projected at $107–$110.6 million ($1.30–$1.35 diluted EPS).
• Q4 2026 revenue guidance set at $344.7–$364.6 million (8.3–14.6% growth); Adjusted EBITDA at $57.9–$62.9 million; Adjusted EPS at $0.53–$0.58.
• Anticipates 2027 revenue growth of mid-teens, driven by 1.3 million new lives from the recent selling season, with most launching in Q1 2027 and hundreds of thousands mid-year.
• Total expected covered lives at year-end 2027: 8.3 million across 660+ clients.
• Management expects to taper investment spending in 2027, potentially allowing incremental gross profit to flow through to EBITDA, though no formal long-term margin target was provided.

Business Segments and Product Lines:

• 2026 Selling Season: Generated record 1.3 million new covered lives and 85+ new clients; 100% retention of existing base with ~20% expansion/upsell activity.
• Product Mix: Near 100% attach rate for Progeny Rx among new clients (projected 95–96% overall next year); over 3 million lives will access expanded products in 2027.
• New Offering: "Progeny Select" (fully insured market) was immaterial to current results as infrastructure and relationships are being built for future scaling.
• Client Diversity: New client base includes prestigious universities, a MAG-7 tech leader, a top U.S. bank, and the largest public employee health benefit fund; client sizes range from 1,000 to 100,000+ lives.
• Pharmacy Attach: Strong adoption of pharmacy programs with new logos reinforces differentiation and value proposition.

Market and Competitive Landscape:

• Market Trends: High medical cost inflation and employer focus on family building/women's health driving demand; 1 in 5 adults face infertility (CDC data).
• Competition: Market consolidation occurring as non-profitable or unscalable competitors reduce operations or exit; one competitor exited a year ago, another is significantly pausing.
• Market Share: Progeny capturing value-driven demand from discerning employers; competitive conversions occurred but were not the primary growth driver.
• Differentiation: Proven track record in cost containment, clinical outcomes, and member experience cited as key differentiators against rivals.
• Pipeline: Strongest sales momentum and pipeline volume ever, including multiple "jumbo" accounts, positioning the firm for the 2027 season.

Risks and Challenges:

• Medical Cost Inflation: Persistent inflation trends in general healthcare could pressure employer budgets, though Progeny's cost containment mitigates this risk.
• Utilization Variability: Utilization rates fluctuate seasonally and by industry; Q3 saw slightly higher usage due to deferred summer treatments, but trends are returning to normal.
• Integration Risks: Ongoing integration of purchased companies and platform expansion requires continued investment.
• Regulatory/Compliance: Standard risks regarding SEC filings and forward-looking statements.

Management Commentary and Tone:

• Tone: Confident and optimistic, citing record performance, healthy member engagement, and strong pipeline as evidence of market demand.
• Strategy: Emphasis on differentiated solutions, disciplined go-to-market execution, and channel partnerships (e.g., Cigna).
• Capital Allocation: Active share repurchases and reinvestment in product/platform capabilities while maintaining high cash conversion.
• Client Sentiment: Strong alignment with employers seeking cost control and high-quality outcomes for the millennial workforce.

Analyst Questions and Answers:

• Public Sector Economics: CalPERS and similar large public sector clients expected to have slightly lower utilization than average but consistent margin profiles based on underwriting.
• 2027 Margin Expansion: Management expects investment tapering in 2027 to support potential margin expansion, though 2027 specific guidance will be provided at year-end.
• Competitive Takeaways: Large employers facing challenges with prior fertility partners are in discussion; however, conversions from competitors were not the primary growth driver this season.
• Utilization Trends: Q3 utilization was slightly higher than expected due to seasonal deferrals; Q4 shows normal patterns with strong October/November activity.
• Partnership with Cigna: No major new learnings; successful sales activity driven by standard consulting partner dynamics and operational integration capabilities.
  EL Files: Expect >50% of the client base to provide full eligibility files by year-end.
• Brownfield vs. Greenfield: New business is relatively balanced, slightly more brownfield; utilization is driven by industry mix, not acquisition type.
• Gross/S&A Margins: Gross margin expansion largely attributed to reduced stock comp; S&A continues to see investment in GTM resources and platform expansion.
• Macro Trends: Despite high inflation and GLP-1 costs, demand remains robust due to the critical nature of fertility coverage for the workforce.

Other Key Points:

• No new major "puts and takes" identified for 2027 guidance beyond the 1.3 million new lives and potential mid-year launches.
• Member engagement metrics remain consistent with long-established ranges; seasonality in Q3 was temporary.
• Progeny Select continues to be a long-term growth focus despite current immaterial contribution.
• The client base has reached its most diverse configuration historically, with no single client or economy sector making an outsized contribution.